Resource Summary Report

Generated by kravitz2 on Jul 30, 2026

Vivli

RRID:SCR_018080
Type: Tool

Proper Citation

Vivli (RRID:SCR_018080)

Resource Information

URL: https://vivli.org/

Proper Citation: Vivli (RRID:SCR_018080)

Description: Independent, non-profit organization that has developed global data-sharing and analytics platform to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through creation and implementation of sustainable global data-sharing enterprise. Our focus is on sharing individual participant-level data from completed clinical trials. Users can search listed studies, request data sets from data contributors, aggregate data, or share data of their own. Vivli (Center for Clinical Research Data) is launching a portal to share participant-level data from COVID trials.

Resource Type: data or information resource, service resource, nonprofit organization

Keywords: Global data sharing, clinical research data, data, sharing, analytical platform, clinical trial, COVID-19-related trials

Related Condition: COVID-19

Funding: Doris Duke Charitable Foundation ;
Leona M. and Harry B. Helmsley Charitable Trust ;
Lyda Hill Philanthropies ;
Phrma

Availability: Restricted

Resource Name: Vivli

Resource ID: SCR_018080

Alternate IDs: DOI:10.17616/R3SB9S, DOI:10.25504/FAIRsharing.uovQrT, DOI:10.25934, r3d100012823

Alternate URLs: https://vivli.org/vivli-covid-19-portal-2/, https://doi.org/10.17616/R3SB9S, https://doi.org/10.17616/r3sb9s, https://doi.org/10.25934/, https://dx.doi.org/10.25934/, https://fairsharing.org/10.25504/FAIRsharing.uovQrT, https://doi.org/10.17616/R3SB9S

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260729T044437+0000

Ratings and Alerts

No rating or validation information has been found for Vivli.

No alerts have been found for Vivli.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 1532 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Lundahl A, et al. (2026) AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma. British journal of clinical pharmacology, 92(1), 257.

Gormley ME, et al. (2026) Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study. Developmental medicine and child neurology, 68(2), 227.

Kato M, et al. (2026) Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial. Psychiatry and clinical neurosciences, 80(1), 76.

de la Rambelje MA, et al. (2026) Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD. Diabetes, obesity & metabolism, 28(1), 750.

Giblin K, et al. (2026) Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism, 28(1), 83.

Lange R, et al. (2026) A real-world study to describe the effectiveness and usage patterns of hyoscine butylbromide plus tablets in patients with dysmenorrhoea. Women's health (London, England), 22, 17455057251406956.

Tuttle KR, et al. (2026) Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review. Diabetes, obesity & metabolism, 28(1), 16.

Yoneda M, et al. (2026) Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis. Diabetes, obesity & metabolism, 28(1), 763.

Tamura R, et al. (2026) Incidence of Diabetic Ketoacidosis in Dapagliflozin-Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study. Pharmacoepidemiology and drug safety, 35(1), e70294.

Gu W, et al. (2026) Efficacy and safety of iGlarLixi versus IDegAsp by baseline ?-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study. Diabetes, obesity & metabolism, 28(1), 242.

le Roux CW, et al. (2026) Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). Diabetes, obesity & metabolism, 28(1), 337.

Shukla AP, et al. (2026) Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial. Diabetes, obesity & metabolism, 28(1), 452.

Wanin S, et al. (2026) Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry. Allergy, 81(1), 292.

Saar M, et al. (2026) Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS. Cancer medicine, 15(1), e71343.

Gazzah A, et al. (2026) Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. Translational oncology, 63, 102615.

Li X, et al. (2026) People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment. Obesity (Silver Spring, Md.), 34(1), 114.

He AR, et al. (2026) Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study. Hepatology communications, 10(1).

Martin CK, et al. (2025) Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature medicine, 31(9), 3141.

Zwing N, et al. (2025) Mapping immune activity in HPV-negative head and neck squamous cell carcinoma: a spatial multiomics analysis. Journal for immunotherapy of cancer, 13(6).

Hochmair M, et al. (2025) Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer. Future oncology (London, England), 21(15), 1867.